NeuroSense Therapeutics (NASDAQ:NRSN) Given “Hold” Rating at Maxim Group

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “hold” rating reiterated by Maxim Group in a research note issued on Monday,Benzinga reports.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock traded down $0.05 during trading hours on Monday, reaching $0.81. The company’s stock had a trading volume of 98,242 shares, compared to its average volume of 260,371. NeuroSense Therapeutics has a one year low of $0.51 and a one year high of $2.33. The company has a market capitalization of $11.07 million, a P/E ratio of -0.95 and a beta of 1.38. The stock’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics as of its most recent filing with the SEC. 1.04% of the stock is owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.